AstraZeneca explores potential transaction with Acerta
Published Mon, Dec 14, 2015 · 08:31 AM
[PARIS] AstraZeneca Plc said it's exploring potential strategic options with Acerta Pharma BV, a maker of cancer medicines.
There can be no certainty that a "transaction will ultimately be entered into, or as to the terms of any transaction," the London-based company said in a statement.
BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Cordlife served letter of demand, notice of claim from customers
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director